AbbVie Stock Forecast, Price & News

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AbbVie stock.
View analyst ratings for AbbVie or view top-rated stocks.

16 brokers have issued 1-year price targets for AbbVie's stock. Their ABBV stock forecasts range from $135.00 to $200.00. On average, they predict AbbVie's stock price to reach $159.75 in the next year. This suggests a possible upside of 3.9% from the stock's current price.
View analysts' price targets for AbbVie or view top-rated stocks among Wall Street analysts.

AbbVie's stock was trading at $135.40 on January 1st, 2022. Since then, ABBV stock has increased by 13.6% and is now trading at $153.80.
View the best growth stocks for 2022 here.

AbbVie is scheduled to release its next quarterly earnings announcement on Friday, July 29th 2022.
View our earnings forecast for AbbVie.

AbbVie Inc. (NYSE:ABBV) announced its quarterly earnings results on Friday, April, 29th. The company reported $3.16 earnings per share for the quarter, beating the consensus estimate of $3.15 by $0.01. The business earned $13.36 billion during the quarter, compared to analysts' expectations of $13.61 billion. AbbVie had a trailing twelve-month return on equity of 159.31% and a net margin of 22.00%. AbbVie's revenue for the quarter was up 2.7% on a year-over-year basis. During the same period in the previous year, the business posted $2.95 earnings per share.
View AbbVie's earnings history.

AbbVie announced a quarterly dividend on Thursday, June 23rd. Stockholders of record on Friday, July 15th will be paid a dividend of $1.41 per share on Monday, August 15th. This represents a $5.64 annualized dividend and a dividend yield of 3.67%. The ex-dividend date of this dividend is Thursday, July 14th.
View AbbVie's dividend history.

AbbVie(NYSE:ABBV) pays an annual dividend of $5.64 per share and currently has a dividend yield of 3.68%. AbbVie has been increasing its dividend for 50 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of AbbVie is 80.92%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, AbbVie will have a dividend payout ratio of 47.55% next year. This indicates that AbbVie will be able to sustain or increase its dividend.
View AbbVie's dividend history.

AbbVie issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of $13.92-$14.12 for the period, compared to the consensus earnings per share estimate of $14.11. The company issued revenue guidance of $59.40 billion-$59.40 billion, compared to the consensus revenue estimate of $60.04 billion.

580 employees have rated AbbVie CEO Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among AbbVie's employees.

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Eli Lilly and (LLY), Pfizer (PFE), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Corcept Therapeutics (CORT), Pacira BioSciences (PCRX), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR) and Omeros (OMER).
View all of ABBV's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Wheaton Precious Metals (WPM), Rogers Communications (RCI) and Open Text (OTEX).

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie's stock is owned by a number of institutional and retail investors. Top institutional investors include Park National Corp OH (0.00%) and Stonebridge Capital Management Inc. (0.00%). Company insiders that own AbbVie stock include Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Edward J Rapp, Elaine K Sorg, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and Timothy J Richmond.
View institutional ownership trends for AbbVie.

ABBV stock was sold by a variety of institutional investors in the last quarter, including Park National Corp OH, and Stonebridge Capital Management Inc.. Company insiders that have sold AbbVie company stock in the last two years include Brian L Durkin, Carlos Alban, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, and Timothy J Richmond.
View insider buying and selling activity for AbbVie or view top insider-selling stocks.

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ABBV stock can currently be purchased for approximately $153.80.

AbbVie (NYSE:ABBV) has a market capitalization of $271.78 billion and generates $56.20 billion in revenue each year. The company earns $11.54 billion in net income (profit) each year or $6.97 on an earnings per share basis.

AbbVie employs 50,000 workers across the globe.

AbbVie was founded in 2013.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The official website for AbbVie is www.abbvie.com. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049.